Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast – Global Analysis
Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer’s disease drug market.
From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year 2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug Market.
Renub Research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast – Global Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer’s Disease Drug Market.
Present & Pipeline Drugs Studied in this Report
1. Namenda
2. Ebixa
3. Axura
4. Aricept
5. Nootropil
6. Exelon
7. Memary
8. Solanezumab
9. LuAe58054
This report contains 10 chapters.
(Chapter 1): Executive Summary
(Chapter 2): This Chapter is divided into 2 parts
A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018
B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)
(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials
(Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All the 9 Alzheimer’s drug mentioned above have been covered in this chapter.
(Chapter 5): This chapter talks about Alzheimer’s Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018.
(Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points:
A. Clinical Development Stage
B. Pipeline Drug Sales Performance
C. Recent Clinical Development
D. Different Companies Deal
E. Investment
(Chapter 7): This chapter speaks of Alzheimer’s Drugs Company deals in four areas
A. Strategic Alliances in Alzheimer’s Disease Drug Market
B. Licensing Agreement in Alzheimer’s Disease Drug Market
C. Collaboration Deal in Alzheimer’s Disease Drug Market
D. Merger & Acquisition in Alzheimer’s Disease Drug Market
(Chapter 8): This chapter studies Funding in Alzheimer’s Disease Drugs Research. We have covered 5 institutes which provides fund for the research.
A. National Institute of Health
B. Alzheimer's Association
C. Cure Alzheimer’s Fund
D. Alzheimer’s Drug Discovery Foundation
E. BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]
(Chapter 9): This chapter studies Growth Factors Driving the Alzheimer’s Disease Drug Market.
(Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimer’s Disease Drug Market.
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year 2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug Market.
Renub Research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast – Global Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer’s Disease Drug Market.
Present & Pipeline Drugs Studied in this Report
1. Namenda
2. Ebixa
3. Axura
4. Aricept
5. Nootropil
6. Exelon
7. Memary
8. Solanezumab
9. LuAe58054
This report contains 10 chapters.
(Chapter 1): Executive Summary
(Chapter 2): This Chapter is divided into 2 parts
A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018
B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)
(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials
(Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All the 9 Alzheimer’s drug mentioned above have been covered in this chapter.
(Chapter 5): This chapter talks about Alzheimer’s Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018.
(Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points:
A. Clinical Development Stage
B. Pipeline Drug Sales Performance
C. Recent Clinical Development
D. Different Companies Deal
E. Investment
(Chapter 7): This chapter speaks of Alzheimer’s Drugs Company deals in four areas
A. Strategic Alliances in Alzheimer’s Disease Drug Market
B. Licensing Agreement in Alzheimer’s Disease Drug Market
C. Collaboration Deal in Alzheimer’s Disease Drug Market
D. Merger & Acquisition in Alzheimer’s Disease Drug Market
(Chapter 8): This chapter studies Funding in Alzheimer’s Disease Drugs Research. We have covered 5 institutes which provides fund for the research.
A. National Institute of Health
B. Alzheimer's Association
C. Cure Alzheimer’s Fund
D. Alzheimer’s Drug Discovery Foundation
E. BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]
(Chapter 9): This chapter studies Growth Factors Driving the Alzheimer’s Disease Drug Market.
(Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimer’s Disease Drug Market.
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
1. EXECUTIVE SUMMARY
2. WORLDWIDE – ALZHEIMER’S DISEASE DRUG MARKET ANALYSIS
2.1 Alzheimer’s Disease Drug Market & Forecast
2.2 Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential)
3. FAILED ALZHEIMER’S DRUGS
3.1 Dismal Results but Still Trying Again
4. WORLDWIDE – ALZHEIMER’S DISEASE DRUG MARKET SHARE & FORECAST
5. WORLDWIDE – ALZHEIMER’S DRUG BRANDS MARKET PERFORMANCE
5.1 Exelon (Rivastigmine) – Past, Present & Future Market
5.2 Aricept (Donepezil) – Past, Present & Future Market
5.3 Memantine (Namenda, Ebixa, Axura, Memary) Past, Present & Future Market
5.3.1 Namenda (Memantine) – Past, Present & Future Market
5.3.2 Ebixa (Memantine) – Past, Present & Future Market
5.3.3 Axura (Memantine) – Past, Present & Future Market
5.3.4 Memary (Memantine) – Past, Present & Future Market
5.4 Nootropil (Piracetam) – Past, Present & Future Market
6. PIPELINE DRUGS ANALYSIS IN ALZHEIMER’S DISEASE MARKET
6.1 Solanezumab (LY2062430) – Eli Lilly
6.1.1 Clinical Development Stage
6.1.1.1 Phase – II
6.1.1.2 Phase – III
6.1.2 Solanezumab Drug Sales (2017 – 2020)
6.1.3 Recent Clinical Development
6.2 LuAE58054 – Lundbeck
6.2.1 Clinical Development Stage
6.2.1.1 Phase – II
6.2.2 LuAE58054 Drug Sales (2017 – 2018)
6.2.3 Deal on LuAE58054
6.3 Gantenerumab – Roche
6.3.1 Clinical Development Stage
6.3.1.1 Phase – I
6.3.1.2 Phase – II & III
6.3.1.3 Phase – III
6.3.2 Investment in Gantenerumab Drug
6.4 Crenezumab – Genentech
6.4.1 Clinical Development Stage
6.4.1.1 Phase – II
6.4.2 Investment in Crenezumab Drug
6.5 TRx0237 (LMTX) – TauRx Therapeutics Ltd.
6.5.1 Clinical Development Stage
6.5.1.1 Phase – II
6.5.1.2 Phase – III
6.5.2 Investment in TRx0237 (LMTX) Drug
6.6 MK-8931 – Merck
6.6.1 Clinical Development Stage
6.6.1.1 Phase – II/III
6.7 ABT-126 – AbbVie
6.7.1 Clinical Development Stage
6.7.1.1 Phase – I
6.7.1.2 Phase – II
6.8 AZD-1446 – Targacept/AstraZeneca
6.8.1 Clinical Development Stage
6.8.1.1 Phase – I
6.8.2 Recent Development
7. M&A, LICENSING AGREEMENT, STRATEGIC ALLIANCES & COLLABORATION DEALS IN ALZHEIMER’S DISEASE DRUG MARKET
7.1 Strategic Alliances in Alzheimer’s Disease Drug Market
7.2 Licensing Agreement in Alzheimer’s Disease Drug Market
7.3 Collaboration Deal in Alzheimer’s Disease Drug Market
7.4 Merger & Acquisition in Alzheimer’s Disease Drug Market
8. FUNDING IN ALZHEIMER’S DISEASE DRUGS RESEARCH
8.1 National Institute of Health
8.2 Alzheimer's Association
8.3 Cure Alzheimer’s Fund
8.4 Alzheimer’s Drug Discovery Foundation
8.5 BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]
9. KEY DRIVERS OF GROWTH IN GLOBAL ALZHEIMER’S DISEASE DRUG MARKET
9.1 Aging Population
9.1.1 Global Ageing Indicators
9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 – 2050
9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 – 2050
9.2 Unmet Medical Needs
9.3 The Launches of New Drugs Solanezumab, LuAE58054, Gantenerumab & TRx0237 Will Boost the Alzheimer’s Market Through 2018
9.4 Future Drugs for Disease Modification in Alzheimer’s Disease
10. KEY CHALLENGES IN THE GLOBAL ALZHEIMER’S DISEASE DRUG MARKET
10.1 Lack of Validated Targets & Lack of Animal Models
10.2 Barriers in the Design and Implementation of Clinical Trials
10.3 Barriers in Academia & Regulatory Issues
10.4 Alzheimer’s Drug Failure: Insinuation for Future R&D in Neuroscience
10.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies
10.6 Research Setbacks and Stepping Stones
2. WORLDWIDE – ALZHEIMER’S DISEASE DRUG MARKET ANALYSIS
2.1 Alzheimer’s Disease Drug Market & Forecast
2.2 Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential)
3. FAILED ALZHEIMER’S DRUGS
3.1 Dismal Results but Still Trying Again
4. WORLDWIDE – ALZHEIMER’S DISEASE DRUG MARKET SHARE & FORECAST
5. WORLDWIDE – ALZHEIMER’S DRUG BRANDS MARKET PERFORMANCE
5.1 Exelon (Rivastigmine) – Past, Present & Future Market
5.2 Aricept (Donepezil) – Past, Present & Future Market
5.3 Memantine (Namenda, Ebixa, Axura, Memary) Past, Present & Future Market
5.3.1 Namenda (Memantine) – Past, Present & Future Market
5.3.2 Ebixa (Memantine) – Past, Present & Future Market
5.3.3 Axura (Memantine) – Past, Present & Future Market
5.3.4 Memary (Memantine) – Past, Present & Future Market
5.4 Nootropil (Piracetam) – Past, Present & Future Market
6. PIPELINE DRUGS ANALYSIS IN ALZHEIMER’S DISEASE MARKET
6.1 Solanezumab (LY2062430) – Eli Lilly
6.1.1 Clinical Development Stage
6.1.1.1 Phase – II
6.1.1.2 Phase – III
6.1.2 Solanezumab Drug Sales (2017 – 2020)
6.1.3 Recent Clinical Development
6.2 LuAE58054 – Lundbeck
6.2.1 Clinical Development Stage
6.2.1.1 Phase – II
6.2.2 LuAE58054 Drug Sales (2017 – 2018)
6.2.3 Deal on LuAE58054
6.3 Gantenerumab – Roche
6.3.1 Clinical Development Stage
6.3.1.1 Phase – I
6.3.1.2 Phase – II & III
6.3.1.3 Phase – III
6.3.2 Investment in Gantenerumab Drug
6.4 Crenezumab – Genentech
6.4.1 Clinical Development Stage
6.4.1.1 Phase – II
6.4.2 Investment in Crenezumab Drug
6.5 TRx0237 (LMTX) – TauRx Therapeutics Ltd.
6.5.1 Clinical Development Stage
6.5.1.1 Phase – II
6.5.1.2 Phase – III
6.5.2 Investment in TRx0237 (LMTX) Drug
6.6 MK-8931 – Merck
6.6.1 Clinical Development Stage
6.6.1.1 Phase – II/III
6.7 ABT-126 – AbbVie
6.7.1 Clinical Development Stage
6.7.1.1 Phase – I
6.7.1.2 Phase – II
6.8 AZD-1446 – Targacept/AstraZeneca
6.8.1 Clinical Development Stage
6.8.1.1 Phase – I
6.8.2 Recent Development
7. M&A, LICENSING AGREEMENT, STRATEGIC ALLIANCES & COLLABORATION DEALS IN ALZHEIMER’S DISEASE DRUG MARKET
7.1 Strategic Alliances in Alzheimer’s Disease Drug Market
7.2 Licensing Agreement in Alzheimer’s Disease Drug Market
7.3 Collaboration Deal in Alzheimer’s Disease Drug Market
7.4 Merger & Acquisition in Alzheimer’s Disease Drug Market
8. FUNDING IN ALZHEIMER’S DISEASE DRUGS RESEARCH
8.1 National Institute of Health
8.2 Alzheimer's Association
8.3 Cure Alzheimer’s Fund
8.4 Alzheimer’s Drug Discovery Foundation
8.5 BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]
9. KEY DRIVERS OF GROWTH IN GLOBAL ALZHEIMER’S DISEASE DRUG MARKET
9.1 Aging Population
9.1.1 Global Ageing Indicators
9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 – 2050
9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 – 2050
9.2 Unmet Medical Needs
9.3 The Launches of New Drugs Solanezumab, LuAE58054, Gantenerumab & TRx0237 Will Boost the Alzheimer’s Market Through 2018
9.4 Future Drugs for Disease Modification in Alzheimer’s Disease
10. KEY CHALLENGES IN THE GLOBAL ALZHEIMER’S DISEASE DRUG MARKET
10.1 Lack of Validated Targets & Lack of Animal Models
10.2 Barriers in the Design and Implementation of Clinical Trials
10.3 Barriers in Academia & Regulatory Issues
10.4 Alzheimer’s Drug Failure: Insinuation for Future R&D in Neuroscience
10.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies
10.6 Research Setbacks and Stepping Stones
LIST OF FIGURES:
Figure 2 1: Worldwide – Alzheimer’s Disease Drug Market (Million US$), 2003 – 2012
Figure 2 2: Worldwide – Forecast for Alzheimer’s Disease Drug Market (Million US$), 2013 – 2018
Figure 2 3: Worldwide – Unmet Alzheimer’s Disease Drug Market (Million US$), 2010 – 2012
Figure 2 4: Worldwide – Forecast for Unmet Alzheimer’s Disease Drug Market (Million US$), 2013 – 2018
Figure 5 1: Worldwide – Exelon Alzheimer’s Drug Sales (Million US$), 2005 – 2012
Figure 5 2: Worldwide – Forecast for Exelon Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 3: Worldwide – Aricept Alzheimer’s Drug Sales (Million US$), 2004 – 2012
Figure 5 4: Worldwide – Forecast for Aricept Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 5: Worldwide – Namenda Alzheimer’s Drug Sales (Million US$), 2003 – 2012
Figure 5 6: Worldwide – Forecast for Namenda Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 7: Worldwide – Ebixa Alzheimer’s Drug Sales (Million US$), 2003 – 2012
Figure 5 8: Worldwide – Forecast for Ebixa Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 9: Worldwide – Axura Alzheimer’s Drug Sales (Million US$), 2003 – 2012
Figure 5 10: Worldwide – Forecast for Axura Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 11: Worldwide – Memary Alzheimer’s Drug Sales (Million US$), 2011 – 2012
Figure 5 12: Worldwide – Forecast for Memary Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 13: Worldwide – Nootropil Alzheimer’s Drug Sales (Million US$), 2004 – 2012
Figure 5 14: Worldwide – Forecast for Nootropil Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 6 1: Worldwide – Forecast for Pipeline Solanezumab Drug Sales (Million US$), 2017 – 2020
Figure 6 2: Worldwide – Forecast for Pipeline LuAE58054 Drug Sales (Million US$), 2017 – 2018
Figure 8 1: National Institute of Health – Funding in Alzheimer’s Disease Research (Million US$), 2003 – 2013
Figure 8 2: Alzheimer’s Association – Funding in Alzheimer’s Disease Research (Million US$), 2007 – 2013
Figure 8 3: Cure Alzheimer’s Fund – Funding in Alzheimer’s Disease Research (Million US$), 2007 – 2012
Figure 8 4: Alzheimer’s Drug Discovery Foundation – Funding in Alzheimer’s Disease Research (Million US$), 2007 – 2012
Figure 9 1: Worldwide – Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
Figure 9 2: Worldwide – Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 9 3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 – 2050
Figure 9 4: Worldwide – Pipeline Alzheimer’s Drugs Performance (Million US$), 2009, 2015, 2017
Figure 10 1: Unsuccessful Alzheimer’s Drug Development (Number), 1998 – 2011
Figure 2 1: Worldwide – Alzheimer’s Disease Drug Market (Million US$), 2003 – 2012
Figure 2 2: Worldwide – Forecast for Alzheimer’s Disease Drug Market (Million US$), 2013 – 2018
Figure 2 3: Worldwide – Unmet Alzheimer’s Disease Drug Market (Million US$), 2010 – 2012
Figure 2 4: Worldwide – Forecast for Unmet Alzheimer’s Disease Drug Market (Million US$), 2013 – 2018
Figure 5 1: Worldwide – Exelon Alzheimer’s Drug Sales (Million US$), 2005 – 2012
Figure 5 2: Worldwide – Forecast for Exelon Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 3: Worldwide – Aricept Alzheimer’s Drug Sales (Million US$), 2004 – 2012
Figure 5 4: Worldwide – Forecast for Aricept Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 5: Worldwide – Namenda Alzheimer’s Drug Sales (Million US$), 2003 – 2012
Figure 5 6: Worldwide – Forecast for Namenda Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 7: Worldwide – Ebixa Alzheimer’s Drug Sales (Million US$), 2003 – 2012
Figure 5 8: Worldwide – Forecast for Ebixa Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 9: Worldwide – Axura Alzheimer’s Drug Sales (Million US$), 2003 – 2012
Figure 5 10: Worldwide – Forecast for Axura Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 11: Worldwide – Memary Alzheimer’s Drug Sales (Million US$), 2011 – 2012
Figure 5 12: Worldwide – Forecast for Memary Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 5 13: Worldwide – Nootropil Alzheimer’s Drug Sales (Million US$), 2004 – 2012
Figure 5 14: Worldwide – Forecast for Nootropil Alzheimer’s Drug Sales (Million US$), 2013 – 2018
Figure 6 1: Worldwide – Forecast for Pipeline Solanezumab Drug Sales (Million US$), 2017 – 2020
Figure 6 2: Worldwide – Forecast for Pipeline LuAE58054 Drug Sales (Million US$), 2017 – 2018
Figure 8 1: National Institute of Health – Funding in Alzheimer’s Disease Research (Million US$), 2003 – 2013
Figure 8 2: Alzheimer’s Association – Funding in Alzheimer’s Disease Research (Million US$), 2007 – 2013
Figure 8 3: Cure Alzheimer’s Fund – Funding in Alzheimer’s Disease Research (Million US$), 2007 – 2012
Figure 8 4: Alzheimer’s Drug Discovery Foundation – Funding in Alzheimer’s Disease Research (Million US$), 2007 – 2012
Figure 9 1: Worldwide – Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
Figure 9 2: Worldwide – Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 9 3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 – 2050
Figure 9 4: Worldwide – Pipeline Alzheimer’s Drugs Performance (Million US$), 2009, 2015, 2017
Figure 10 1: Unsuccessful Alzheimer’s Drug Development (Number), 1998 – 2011
LIST OF TABLES:
Table 4 1: Worldwide – Alzheimer’s Disease Drug Market Share (Percent), 2003 – 2012
Table 4 2: Worldwide – Forecast for Alzheimer’s Disease Drug Market Share (Percent), 2013 – 2018
Table 6 1: Alzheimer’s Disease – Investment in Crenezumab Drug (Million US$), 2012
Table 7 1: Strategic Alliances in Alzheimer’s disease Drug Market, 2003 – 2013
Table 7 2: Licensing Agreement in Alzheimer’s disease Drug Market, 2007 – 2013
Table 7 3: Collaboration Deal in Alzheimer’s Disease Drug Market, 2005 – 2013
Table 7 4: Merger & Acquisition (Million US$) in Alzheimer’s disease Drug Market, 2008 – 2013
Table 8 1: BrightFocus Foundation – Funding in Alzheimer’s disease Research (US$), 2010 – 2013
Table 9 1: Global – Ageing Indicators (Percent), 2011/2012 – 2050
Table 9 2: Global – Population (Number), 2011/2012 – 2050
Table 9 3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium Variant)
Table 4 1: Worldwide – Alzheimer’s Disease Drug Market Share (Percent), 2003 – 2012
Table 4 2: Worldwide – Forecast for Alzheimer’s Disease Drug Market Share (Percent), 2013 – 2018
Table 6 1: Alzheimer’s Disease – Investment in Crenezumab Drug (Million US$), 2012
Table 7 1: Strategic Alliances in Alzheimer’s disease Drug Market, 2003 – 2013
Table 7 2: Licensing Agreement in Alzheimer’s disease Drug Market, 2007 – 2013
Table 7 3: Collaboration Deal in Alzheimer’s Disease Drug Market, 2005 – 2013
Table 7 4: Merger & Acquisition (Million US$) in Alzheimer’s disease Drug Market, 2008 – 2013
Table 8 1: BrightFocus Foundation – Funding in Alzheimer’s disease Research (US$), 2010 – 2013
Table 9 1: Global – Ageing Indicators (Percent), 2011/2012 – 2050
Table 9 2: Global – Population (Number), 2011/2012 – 2050
Table 9 3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium Variant)
